Antihypertensives, nitrates and heart failure drugs
Drugs that act on the renin-angiotensin system, calcium channels, vascular smooth muscle and the kidney; nitrates and other vasodilators; diuretics; and the drugs that change outcomes in heart failure, with the emergencies they cause and treat.
By the end of this page you should be able to
- Describe the pharmacology of ACE inhibitors, angiotensin receptor blockers and aldosterone antagonists.
- Compare dihydropyridine and non-dihydropyridine calcium channel blockers.
- Describe the mechanism and adverse effects of nitrates, hydralazine and sodium nitroprusside.
- Classify diuretics by site of action and describe their effects on electrolytes.
- Explain how drugs used in heart failure reduce symptoms or mortality, and outline drugs for hypertensive emergencies.
The renin-angiotensin-aldosterone system
- ACE inhibitors (ramipril, perindopril, enalapril, a prodrug): block conversion of angiotensin I to II and the breakdown of bradykinin. Lower afterload and preload, reduce aldosterone, and slow cardiac and renal remodelling. Adverse: dry cough (bradykinin, about 1 in 10), angioedema (bradykinin, can occur at any time, more common in people of African ancestry), hyperkalaemia, first-dose hypotension, acute kidney injury in bilateral renal artery stenosis or with diuretics and NSAIDs (they dilate the efferent arteriole, lowering glomerular pressure). Teratogenic in the second and third trimesters.
- Angiotensin receptor blockers (candesartan, irbesartan): block AT1 receptors; similar effects without the bradykinin rise, so much less cough (angioedema can still occur, rarely).
- Aldosterone antagonists (spironolactone, eplerenone): block the mineralocorticoid receptor in the collecting duct; potassium-sparing; reduce mortality in heart failure with reduced ejection fraction; spironolactone also blocks androgen receptors (gynaecomastia). Hyperkalaemia, especially with ACE inhibitors and renal impairment.
- ARNI (sacubitril with valsartan): neprilysin inhibition raises natriuretic peptides (vasodilation, natriuresis) while valsartan blocks AT1. Not combined with an ACE inhibitor (angioedema).
Calcium channel blockers
- Dihydropyridines (amlodipine, nifedipine, nimodipine): vascular-selective L-type block; arteriolar dilation; reflex tachycardia (short-acting nifedipine); ankle oedema (precapillary dilation), flushing, headache. Nimodipine reduces delayed ischaemic deficit after subarachnoid haemorrhage.
- Non-dihydropyridines: verapamil (mainly cardiac: slows SA and AV nodes, negative inotrope; constipation) and diltiazem (intermediate). Avoid with beta blockers, in heart failure and in broad-complex tachycardia.
- Poisoning: hypotension, bradycardia and AV block, with hyperglycaemia (L-type block in pancreatic beta cells reduces insulin secretion), a marker of severity. Treatment includes calcium, high-dose insulin euglycaemia therapy, vasopressors and pacing. Modified-release preparations cause delayed, prolonged toxicity.
Vasodilators
- Nitrates (glyceryl trinitrate, isosorbide mononitrate): denitrated (partly by mitochondrial aldehyde dehydrogenase) to nitric oxide, activating soluble guanylyl cyclase; cGMP activates myosin light chain phosphatase and relaxes smooth muscle. Venodilation dominates at low doses (lowers preload and wall stress, relieving angina and pulmonary oedema); arterial and coronary dilation at higher doses. Headache, hypotension, reflex tachycardia, tolerance with continuous use (need a nitrate-free interval), and dangerous hypotension with PDE5 inhibitors. Caution in right ventricular infarction and severe aortic stenosis.
- Sodium nitroprusside: releases NO directly; arterial and venous dilation; titratable within minutes. Releases cyanide (five per molecule), detoxified by rhodanese with thiosulfate to thiocyanate, which accumulates in renal failure. Light-sensitive.
- Hydralazine: arteriolar dilator (mechanism not fully defined); reflex tachycardia and fluid retention; used in pregnancy-related hypertension; slow acetylators get drug-induced lupus.
- Alpha blockers: prazosin (alpha-1, first-dose syncope); phentolamine (non-selective, short-acting) for catecholamine excess and extravasation of vasopressors; labetalol (alpha-1 plus non-selective beta, about 1 to 7 ratio IV) for hypertensive emergencies, including pre-eclampsia and aortic dissection.
- Centrally acting: clonidine (alpha-2 agonist; rebound hypertension if stopped suddenly; overdose mimics opioid toxicity in children), methyldopa (pregnancy).
Diuretics
- Loop diuretics (furosemide): block the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb, the segment that reabsorbs about 25% of filtered sodium; powerful natriuresis. Must reach the lumen by secretion in the proximal tubule (organic anion transporters), so higher doses are needed in renal failure. IV furosemide also causes early venodilation. Hypokalaemia, hypomagnesaemia, metabolic alkalosis, hypocalcaemia (increased calcium excretion), ototoxicity at high doses, hyperuricaemia.
- Thiazides (hydrochlorothiazide, indapamide, chlorthalidone): block the Na-Cl cotransporter in the distal convoluted tubule (about 5% of sodium). Hyponatraemia (especially in older women), hypokalaemia, hypercalcaemia (reduced calcium excretion), hyperglycaemia, gout. Synergise with loop diuretics (sequential nephron blockade).
- Potassium-sparing: aldosterone antagonists, and amiloride (blocks ENaC in the collecting duct). Hyperkalaemia.
- Carbonic anhydrase inhibitors (acetazolamide): proximal tubule; bicarbonate loss and metabolic acidosis; used in acute angle-closure glaucoma and altitude sickness.
- Osmotic (mannitol): filtered, not reabsorbed; holds water in the tubule; also reduces brain water across an intact blood-brain barrier.
Heart failure: symptoms versus survival
In heart failure with reduced ejection fraction, the drugs that reduce mortality block the neurohormonal responses that drive remodelling: ACE inhibitors or ARBs (or ARNI), beta blockers (bisoprolol, carvedilol, metoprolol succinate; started low and titrated slowly once stable), mineralocorticoid antagonists and SGLT2 inhibitors (dapagliflozin, empagliflozin). Loop diuretics relieve congestion but have not been shown to improve survival. Digoxin reduces admissions but not mortality. In acute pulmonary oedema, the treatment is mainly physiological: sit up, oxygen and non-invasive ventilation (lowers preload and afterload and recruits alveoli), nitrates for preload and afterload reduction if blood pressure allows, and diuretics once the patient is fluid overloaded.
Making the answer flow
- Hang every drug on the physiology it changes: preload, afterload, contractility, sodium handling, remodelling.
- Draw the RAAS and mark the drug sites.
- For diuretics, name the transporter, the nephron segment and the electrolyte pattern that follows.
Where marks are lost
- Saying thiazides cause hypercalciuria. They reduce calcium excretion; loops increase it.
- Forgetting that loop diuretics must be secreted into the tubule to work.
- Missing hyperglycaemia as a clue to calcium channel blocker poisoning.
- Giving nitrates to a patient who has taken a PDE5 inhibitor, or with an RV infarct.
Where this meets intensive care
- Sodium nitroprusside donates nitric oxide directly and dilates arterioles and veins within seconds; its cyanide metabolite accumulates with high or prolonged infusions, especially in renal impairment.
- Glyceryl trinitrate needs bioactivation and is mainly a venodilator at lower rates; tolerance develops over hours as the bioactivating enzyme is depleted.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe the pharmacology of ACE inhibitors.
Show answer
- Inhibit ACE (kininase II): less angiotensin II, more bradykinin.
- Effects: arteriolar and venous dilation, reduced aldosterone and ADH, reduced sympathetic facilitation, regression of hypertrophy, reduced proteinuria.
- Most are prodrugs (except captopril, lisinopril); renal excretion.
- Adverse: cough, angioedema, hyperkalaemia, AKI (efferent dilation), first-dose hypotension, teratogenicity.
- Uses: hypertension, HFrEF, post-MI, diabetic nephropathy.
- 2.
Why do ACE inhibitors cause acute kidney injury in some patients?
Show answer
- Glomerular filtration pressure depends on angiotensin II-mediated efferent arteriolar constriction when renal perfusion is low.
- ACE inhibition dilates the efferent arteriole, glomerular pressure falls, GFR falls.
- At risk: bilateral renal artery stenosis, single kidney with stenosis, dehydration, heart failure, NSAIDs and diuretics ("triple whammy").
- Usually reversible on stopping.
- 3.
Compare amlodipine and verapamil.
Show answer
- Both block L-type Ca channels.
- Amlodipine (dihydropyridine): vascular selective, long half-life, vasodilation, oedema, reflex tachycardia; safe with beta blockers.
- Verapamil (phenylalkylamine): cardiac selective, nodal slowing, negative inotropy, constipation; avoid with beta blockers and in HFrEF; antiarrhythmic.
- 4.
How do nitrates work, and why does tolerance develop?
Show answer
- Bioactivated to NO (aldehyde dehydrogenase 2 for GTN), activate soluble guanylyl cyclase, cGMP, protein kinase G, myosin light chain dephosphorylation, smooth muscle relaxation.
- Venodilation reduces preload and LV wall tension (main antianginal effect); coronary dilation and relief of spasm; arteriolar dilation at higher doses.
- Tolerance: impaired bioactivation, oxidative stress, neurohormonal counter-regulation and volume expansion; prevented by a nitrate-free interval.
- 5.
What is the toxicity of sodium nitroprusside?
Show answer
- Each molecule releases five cyanide ions with NO.
- Cyanide converted by rhodanese (needs thiosulfate) to thiocyanate, renally excreted; some binds methaemoglobin to form cyanmethaemoglobin.
- Cyanide toxicity: metabolic acidosis, raised lactate, high venous oxygen saturation, tachyphylaxis, arrhythmias.
- Thiocyanate toxicity in renal failure: confusion, seizures.
- Treatment: stop infusion, hydroxocobalamin, sodium thiosulfate.
- 6.
Classify diuretics and describe the electrolyte disturbances each causes.
Show answer
- Carbonic anhydrase inhibitors (PCT): hyperchloraemic metabolic acidosis, hypokalaemia.
- Osmotic (PCT and loop): hypernatraemia with water loss, or hyponatraemia early.
- Loop (TAL, NKCC2): hypokalaemia, hypomagnesaemia, hypocalcaemia, alkalosis, hyperuricaemia.
- Thiazide (DCT, NCC): hyponatraemia, hypokalaemia, hypercalcaemia, alkalosis, hyperglycaemia, hyperuricaemia.
- K-sparing (CD): hyperkalaemia, acidosis.
- 7.
Which drugs improve survival in heart failure with reduced ejection fraction and why?
Show answer
- ACE inhibitor, ARB or ARNI: block RAAS-driven remodelling and fluid retention.
- Beta blockers: block sympathetic toxicity, reduce arrhythmias and remodelling; start low, titrate.
- Mineralocorticoid antagonists: block aldosterone-induced fibrosis and sodium retention.
- SGLT2 inhibitors: natriuresis, metabolic and renal effects.
- Loop diuretics and digoxin relieve symptoms and admissions without proven survival benefit.
- 8.
A man with a calcium channel blocker overdose is hypotensive and bradycardic. Explain the pharmacology of his treatment.
Show answer
- Calcium IV raises extracellular Ca to overcome channel block (inotropy).
- High-dose insulin euglycaemia therapy: improves myocardial use of glucose (the stressed heart switches to carbohydrate), inotropy; needs glucose and potassium monitoring.
- Vasopressors (noradrenaline, adrenaline) for vasodilation and inotropy; atropine and pacing for bradycardia.
- Decontamination (whole bowel irrigation for modified release), early intensive care; consider ECMO in refractory shock.
- 9.
How do loop diuretics work and why do patients with renal failure need larger doses?
Show answer
- Block NKCC2 on the luminal side of the thick ascending limb; abolish the medullary gradient; large natriuresis.
- Highly protein bound, reach the lumen by active secretion via organic anion transporters in the PCT.
- In renal failure, less secretion (fewer nephrons, competition from retained organic acids), so higher doses are needed to reach the site.
- Ceiling effect per dose; continuous infusion or adding a thiazide for resistance.
Practise this week
- First Part MCQs: cardiovascular
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 8 in the other subjects
- Physiology: The cardiac cycle and pressure-volume loops
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.